

March 17, 2026

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Sub: Disclosure pursuant to the Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations')

Dear Sir/Madam,

In continuation of our previous intimations to the stock exchanges regarding press releases issued by the Company on Euronext Growth Paris, we wish to inform you that, as per French regulations, the Company has issued a press release on Euronext Growth Paris providing an update on the timetable for filing the draft of the mandatory tender offer by the Company on shares of Vinpai, a French société anonyme, and Company's intention not to implement the squeeze-out procedure.

A copy of the same is enclosed herewith. Kindly take the same on your records.

Thanking You,
For Camlin Fine Sciences Limited

Rahul Sawale
Company Secretary
& VP Legal

Encl.: a/a.



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

This press release must not be published, distributed or transmitted, directly or indirectly, in the United States of America, Australia, Canada, South Africa or Japan.

Press release

Update of the timetable of the mandatory tender offer by CAMLIN FINE SCIENCES on Vinpai shares

Filing of the draft of the tender offer expected by early May 2026

No implementation of the squeeze-out procedure

Mumbai (India), March 16, 2026 – 18 h CET

CAMLIN FINE SCIENCES LIMITED, a leading Indian group in shelf life solutions for flavour and health & wellness ingredients, listed on the National Stock Exchange of India Ltd and BSE Ltd. in Mumbai India ("CFSL") reminds that it has completed the acquisition on November 27, 2025, by way of contribution in kind, of a majority stake in the share capital of Vinpai (ISIN: FR001400AXT1; mnémonique : ALVIN) representing 78,68% of share capital et 84.89% of voting rights of Vinpai, at a price of Euro 3.60 per Vinpai share (the "**Block Acquisition**") from significant shareholders (the "**Sellers**").

In addition, CFSL reminds that following the conversion of its convertible bonds issued on October 20, 2025¹ (the "**Convertible Bonds**"), 1,100,000 new ordinary shares of Vinpai were issued in favor of CFSL.

Following the Block Acquisition and the conversion of its Convertible Bonds, CFSL holds 83.82% of Vinpai's share capital and 80.86% of its voting rights.

In its previous press release on December 23, 2025, CFSL had announced that it would file, by end of February 2026 at the latest² with the AMF, pursuant to Articles 234-2 and 235-2 of the General Regulation of the French Stock Markets Authority (AMF) a simplified cash tender offer (*offre publique d'achat simplifiée*) (the "**OPAS**") for the remaining shares of Vinpai, at the same price as that of the Block Acquisition, i.e. Euro 3.60 per Vinpai share.

However, due to administrative constraints specific to CFSL related to Indian foreign exchange regulations and due to the proximity of the announced publication date of Vinpai's 2025 annual financial statements on April 16, 2026³, CFSL announces that it will have to postpone the filing of its OPAS with the purchase price per Vinpai share under the OPAS remaining at Euro 3.60.

Such filing would take place no later than early May 2026 so that the aforementioned Vinpai financial statements may be incorporated into the documentation relating to the OPAS, and into the independent expert's report.

Furthermore, CFSL is looking at the feasible options for restructuring of its group in Europe, to promote synergies among its European subsidiaries and strengthen its presence in Europe. In view of the same, CFSL wishes to keep Vinpai listed.

¹ Cf : Press release of Vinpai on October 20, 2025

² Cf : Press release of CFSL on December 23, 2025

³ Cf : Press release of Vinpai on January 29, 2026



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlins.com



www.camlins.com

Consequently, CFSL announces that it no longer intends to implement a squeeze-out procedure for Vinpai shares from the Euronext Growth Paris market.

Maintaining this listing will allow Vinpai to retain market visibility and have access to the financial markets, ensuring its debt restructuring and supporting the financing of the project's development in Europe, that CFSL group may pursue in the future.

Advisors of CFSL :

Presenting institution



Legal Advisor

FONTAINE
AVOCATS

For further information about CFSL: www.camlinfs.com

Contacts

Camlin Fine Sciences Limited

Investor Relations

secretarial@camlinfs.com

T.: +91 22 6700 1000 -Ext. 402

Disclaimer

This press release does not constitute an offer to sell nor a solicitation of an offer to buy Vinpai shares in any country, nor shall there be any sale of shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This press release constitutes an advertisement and not a prospectus within the meaning of Regulation (EU) no. 2017/1129 of the European Parliament and of the Council of June 14, 2017 (the "**Prospectus Regulation**"). Any decision to purchase shares must be made solely on the basis of publicly available information on the Company.

In France, the issue of bonds convertible into Vinpai shares described above was reserved to an investor falling into the category of beneficiaries defined in the sixteenth resolution of the Company's general meeting dated June 26, 2024, pursuant to article L. 228-91 of the French commercial code and applicable regulatory provisions. Pursuant to article 211-3 of the French stock market authority (*Autorité des marchés financiers*) (the "**AMF**") general regulations and articles 1(4) and 3 of the Prospectus Regulation, the said issue of convertible bonds will not require the publication of a prospectus approved by the AMF.

With respect to Member States of the European Economic Area, no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State. Therefore, such securities may not be and shall not be offered in any Member State other than in accordance with the exemptions of article 1(4) of the Prospectus Regulation or, otherwise, in cases not requiring the publication by the Company of a prospectus under article 3 of the Prospectus Regulation and/or the applicable regulations in such Member State.

This press release and the information it contains are being distributed to and are only intended for persons who are (x) outside the United Kingdom or (y) in the United Kingdom, who constitute "qualified investors" (as this term is defined in the Prospectus Regulation which forms part of domestic law pursuant to European (Withdrawal) Act 2018) and are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "**Order**"), (ii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order ("high net worth companies", "unincorporated associations", etc.)



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

or (iii) other persons to whom an invitation or inducement to participate in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (y)(i), (y)(ii) and (y)(iii) together being referred to as “**Relevant Persons**”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to which this press release

relates will only be available to and engaged with Relevant Persons. This press release is solely intended for Relevant Persons and any person who is not a Relevant Person should not act or rely on this press release or any of its contents.

This press release and the information contained therein does not, and will not, constitute an offer of securities for sale, nor the solicitation of an offer to purchase, Vinpai securities in the United States of America or any other jurisdiction where restrictions may apply. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”). The securities of Vinpai have not been and will not be registered under the Securities Act, and the Company does not intend to conduct a public offering of Vinpai securities in the United States of America.

The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

The information contained in this press release does not constitute an offer of securities in the United States of America, in Australia, in Canada, in South Africa, in Japan nor in any other country. This press release shall not be published, transmitted or distributed, directly or indirectly, into the territory of the United States of America, Australia, Canada, South Africa or Japan.



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com